



## Late-Breaking Abstracts

### General Information

**Abstract submission open: 3 October 2022**

**Abstract submission deadline: 10 October 2022, 21:00 Central European time**

Late-breaking abstracts describe the latest advances that will change our daily clinical practice. They should highlight novel and practice-changing studies. Focus is placed on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the Conference.

Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial; a Phase II study showing anti-tumour activity in a novel context; an early clinical trial with novel proof-of-principle data, or the demonstration of novel cancer biology with therapeutic implications – in each case the results should not have been fully available by the regular abstract submission deadline.

#### **Important note:**

The late-breaking abstract deadline **is not an extension of regular abstract submission deadline.**

### Policy & Regulation

- Abstracts from translational, Phase I, Phase II or Phase III studies for which preliminary data were not available at the time of the regular abstract submission deadline will be considered
- Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.
- Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, explain the details of your study in the body of the abstract.
- The data in the abstract cannot be published (manuscript or abstract) prior to the Conference.

With the submission of a late-breaking abstract to EBCC-13, the presenting author must:

- Submit by the **deadline of 10 October 2022 at 21:00 Central European time**
- Provide rationale on why the abstract should be considered as late-breaking (complete this section in the submission system).
- Ensure submission of the abstract adheres to the regular abstract submission policy and regulations in addition to the specific guidelines listed above.
- Ensure that abstracts contain final results and incorporate statistical analysis. Abstracts submitted stating “results to follow” or similar deferment will not be considered.



## Submission

Late-breaking abstracts can only be submitted online through the submission system which will be available on the conference website from **3 October 2022 to 10 October 2022 (21:00 Central European time)**

## Selection

All late-breaking abstracts will undergo a formal peer-review evaluation by the Scientific Committee and will be judged solely on the data submitted. The final decision on the status of the abstract lies with the Scientific Committee.

Late-breaking abstracts will only be considered for **oral presentation**. If a late-breaking abstract does not meet the criteria for oral presentation, the abstract will be rejected.

**Registration:** Submitting a late breaking abstract for presentation in the EBCC-13 does not constitute registration for the conference. If selected, Late breaking abstract presenters must register to attend the European Breast Cancer Conference in Barcelona.

The presenting author will receive confirmation of acceptance or rejection by **middle of October**.

## Embargo Policy

Late-breaking abstracts and abstracts selected for media for the European Breast Cancer Conference (EBCC-13) are embargoed until the first day of presentation.

Information contained in the abstract as well as additional data and information to be presented **must not be made public before the abstract has been presented at the EBCC-13**.

The first author and co-authors must not release the research/study to news media.

If the policy is violated, the abstract will be automatically withdrawn from presentation and from publication online.

In case of any abstract related queries please contact: [pat.vanhove@eortc.org](mailto:pat.vanhove@eortc.org).